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ABSTRACT  
This paper addresses supply risk in the oncological medicine supply chain (SC) in Colombia. A system dynamics model was developed 
for assessing supply risk impact on SC operation and performance. The costs of risk and logistics operation were evaluated in current 
conditions and in a risk mitigation scenario. The model was based on a systematic analysis of supply networks, mainly concerning the 
reduction of overall SC costs and improving service, quality and opportunity performance index. This article has resulted from research 
into SC risk management (SCRM) carried out by the Universidad Nacional de Colombia’s SEPRO research group. 
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RESUMEN 
En este artículo se aborda la problemática del riesgo de aprovisionamiento en la cadena de suministro (CS) de medicamentos on-
cológicos en Colombia. Se desarrolla un modelo de dinámica de sistemas para evaluar el impacto del riesgo de aprovisionamiento, 
sobre las condiciones de operación y desempeño de la CS. Se valoran los costos del riesgo y de la operación logística en las condi-
ciones actuales y en un escenario con mitigación del riesgo. Las contribuciones del modelo se basan en el análisis sistémico de las 
redes de suministro, principalmente, en la reducción de los costos globales de la cadena y en la mejora de los índices de desempeño 
en oportunidad, calidad  y servicio. Este artículo es el resultado de la investigación de  gestión del riesgo en la cadena de suministro 
(SCRM – SupplyChainRisk Management), realizada por el grupo de investigación SEPRO de la Universidad Nacional de Colombia. 
Palabras clave: riesgo de aprovisionamiento, cadena de suministro, medicamentos oncológicos y dinámica de sistemas. 
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Introduction12 3 
Supply chain (SC) risk refers to the possibility of shortages or dis-
ruptions ocurring regarding materials, product and service flows 
in the SC. This implies the possibility and effect of a mismatch be-
tween supply and demand which might affect customers’ needs 
and expecttions regarding products and services and SC perfor-
mance, thereby causing overcosts and demanding greater effort 
from an organisation (Khan & Burnes, 2007). 
Interruption on any SC level can affect an enterprise in terms of 
product delivery, customer service and operation continuity 
(Juttner, Peck, & Christopher, 2003). 
A study presented by Sanchez-Rodrigues & Naim (2010) observed 
that 60% of the most frequently occurring  problems which can 
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have the greatest effect on SC risk were related to delays, infor-
mation availability, demand knowledge, delivery restrictions and 
SC coordination. Others having lesser effect on SC performance 
were related to infrastructure rigidity, operating costs, SC integra-
tion and technology.  
Sc risk is presented by internal and external or enviromental fac-
tors including control, supply, demand and environmental risks 
(Christopher, 2005). Macro, safety, political, competitive and re-
source risks have been distinguished in similar classification (Manuj 
& Mentzer, 2008). 
Supply risk 
SC risk is defined as the probability of an incident associated with 
inbound supply from individual supplier failures or the supply mar-
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ket occurring, in which its outcome results in purchasing firm ina-
bility to meet customer demand or causes threats to customers’ 
lives and safety (Zsidisin, 2003). This kind of risk has implications 
throughout the SC affecting system productivity levels, inventory 
and cycle times (Eltantawy, Fox, & Giunipero, 2009).   
The danger of shortages and interruptions jeopardise SC objetives, 
especially regarding product availibility, quality conditions and total 
costs. Risk management action must thus be orientated towards 
understanding sources of supply regarding risk and state the best 
ways of managing this (Wu, Blackhurst, & Chidambaram, 2006). 
Context and problems of risk regarding the on-
cological drug SC 
It has been estimated that more than 12 million new cancer cases 
appear in the world each year (IARC/WHO, 2008), most (80%) 
appearing in developing countries (Ministerio de la Proteccion So-
cial de la República de Colombia, 2010); 62,660 new cancer cases 
ocurred in Colombia in 2008 (IARC/WHO, 2008). According to 
the last Basic Indicators for Monitoring Millenium Development 
Objectives report, Colombia’s mortality rate was 76.5 per 100,000 
inhabitants; more than 34,000 people died in 2010 due to cancer 
(PAHO/MPS/INS, 2010).  
Colombian pharmaceutical policy shows that some of the main 
problems in the Colombian health system are related to poor sup-
ply and availability of essential medicines.  Regarding pharmaceuti-
cal policy, it was stated that only 63% of all insured people at-
tended by the system and who were prescribed medicine (in 2008) 
received the complete formulation, 15.8% received it poorly and 
21.2% did not received anything at all (Consejo Nacional de Polí-
tica Económica y Social – DNP, 2012).  
Problems regarding medicine supply, availability and supply is a 
critical Sc risk affecting Colombian patients and the population in 
general, due to public health, social and economic implications for 
the country.   
A shortage of medicines affects the continuity of oncological treat-
ment, thereby endangering patients’ health due to adjustments and 
changes in treatment shemes. At international level, it has been 
identified that oncological medicine shortages have forced treating 
physicians to set application priorities on patients and changes in 
treatment. For example,  capecitabin may be substituted for 5-
flourouracil in adjuvant therapy for colorectal cancer, altough this 
kind of treatment option has not been proved regarding a cure for 
cancer (Chapner, 2011).  
A shortage of medicines forces the search for substitutes thereby 
causing overcosts due to the difference in prices for available med-
icine on the market (United Nations, 2013).   
A shortage of active agents has ocurred in Colombia, such as 5-
fluorouracyl, azatioprine, citarabin, chlorambucyl, doxorubicin, 
mercaptopurin, metotrexate and tioguanine. This situation has 
caused increased costs for the Colombian health system due to 
administrative weakening in contingency operations when search-
ing for medicines on the market and purchasing decisions concern-
ing trading agents having diferent levels of intermediation. 
Research methodology 
The study was focused on healthcare institutions (HCI) which are 
enabled to provide clinical oncologicy services (Diagnosis Support 
and Therapeutical Complementation Group code 709, according 
to the Checking Procedures for Conditions for Evaluating Onco-
logical Services’ Handbook, Ministerio de Salud y Protección So-
cial, 2012) identified from HCI special registration data (Ministerio 
de Salud y Proteccion Social, 2012).  
Such HCI in Colombia providing clinical oncology services includes 
217 hospitals and specialised clinical centres. A sample of 42 HCI 
was taken, according to the scope of data collection planning and 
programming pertinent resources. Sunter’s method was used for 
selecting the HCI, using proportional likelihood for sampling con-
cerning HCI size and number of oncology patients attended (Särn-
dal, Swensson, & Wretman, 1992).  
Selecting drugs 
Doxorrubicine’s active compounds were defined as study subject 
medicine in this research, considering Colombian Health and So-
cial Protection Ministry information concerning such active princi-
ples which had a regular supply pattern during the past year, even 
though a shortage in the system was reported.  
Doxorrubicine is used as chemotherapy medicine and is sold in 
two presentations: 10 mg and 50 mg vials. It is used for treating 
non-Hodgkin’s lymphoma, multiple myeloma (bone marrow cell 
cancer), acute leukaemia, Kaposi’s sarcoma, Ewing’s sarcoma, 
Wilm’s tumour and breast, suprarenal crust, endometrium, lung 
and ovarian cancer, in addition to cancer occurring in other parts 
of the body (American Cancer Society, 2011). 
The SISMED (Ministerio de Salud y Proteccion Social, 2012) data-
base, concerning units sold and prices, reported 229,573 units of 
doxorrubicine being sold in Colombia during 2011. 
Identifying, assessing and analysing risk 
SC risk was identified, assessed and analysed using risk manage-
ment methodology with a systemic focus, as appears in Figure 1. 
Three stages were considered: contextualisation, assessment and 
decision-making and feedback. Interaction between these stages 
led to dealing with the complete cycle of risk management where 
system performance is assessed as time elapses, allowing manage-
ment action to be evaluated according to danger level and suscep-
tibility to risk.  
 
Figure 1. Risk management methodology 
Stages 1 and 2 are dealt with in this research; stage 3 will be re-
searched later on. 
Risk relational theory was used for answering key theorical and 
practical questions regarding the first stage concerning how and 
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why something is considered a risk. At least three conceptual ele-
ments concerning risk definition must be considered: an object, 
the damage and a link based on some kind of causality between 
the object and the damage (Boholm & Corvellec, 2011). The ob-
ject becomes a risk factor causing a risk generator agent and can 
be an internal or external circumstance, natural phenomena or 
patterns within a social system. 
Damage or risk consists of adverse circumstances which can be 
materialised and linkage is the systemic association between risk 
objects and objects at risk which can be stronger than others. 
Four supply risks were identified concerning conceptualisation 
(stage 1,  Figure 2): supply delay, disruption in supply, differences 
in quantities received and demand forecast errors. Such risks con-
cerned a definition of internal and external risk factors; depleting 
a drug’s active compounds, affects pharmaceutical industry drug 
production due to scarcity of raw materials. Drug availability on 
the market depends on market supply and demand dynamics. Lo-
gistics system capacity is associated with response times and qual-
ity regarding drug management and delivery. There are also asym-
metries of information which are a critical risk factor in SC links 
resulting from power relationships, competition conditions in the 
provider market, low coordination between SC agents and limited 
use of communication and information technologies. 
 
Figure 2. Stage 1. Risk contextualisation 
Supply risk implications for the system were summarised into two 
effects: drug shortage in the SC and risk costs  resulting from risk 
materialisation. 
Risk assessment methodology was used in stage 2 (assessment), 
considering the likelihood of ocurrence and risk impact. Likelihood 
and impact coring scales were set, which allowed establishing risk 
areas: severe, major, medium and minor (Figure 3). It was found 
that disruption risks and delays in supply were rated severe and 
major; the risk of difference in received numbers was rated major 
and medium and error risk regarding forecasting demand was 
rated medium. 
The expression presented by Liu, Xu, Li, Wang & Wu (2012) was 
used for quantifying the danger of risk:  
Risk exposure = P (NO) * L (NO)              (1)  
where: 
P(NO) was the likelihood of a negative result, and 
L(NO) was loss or effect due to the result.  
System dynamics (SD) application 
The system dynamics (SD) domain developed at the Massachusetts 
Institute of Technology (MIT) in 1950 by Jay Forrester is based on 
the structure and dynamics of complex systems. Control engi-
neering and non-linear dynamic systems theory ststes that SD are 
used for developing formal models and simulation, leading to cap-
turing complex dynamics for creating a favorable environment for 
learning and designing policy (Sterman, 2002). 
 
Figure 3. Risk evaluation 
SD combines the theory, methods and philosophy needed for an-
alysing economic , medicine, engineering patterns and other issues 
(Forrester, 1991). 
Causal diagrams are used in system dynamics methodology for 
representing causal relationships and inter-dependence between 
variables and Forrester or flow diagrams to represent system sta-
tus, feedback and decision-making regarding the information so 
obtained (Sterman, 2000). 
Figure 2 resulted from applying the causal diagram representing 
the current relationship between risk factors, risks and effects.  
System dynamics model  
The structure of the system based on representation of flows and 
drug accumulation in the different SC are presented in the system 
dynamics model. They do not represent a specific node in the SC 
or a physical place for storage or distribution; instead, they consist 
of product flows and accumulation in the system.  
The danger of risk concerning SC is posed by the risk factor con-
cerning supply, associated with the provider market, drug availa-
bility on the market, logistics services and the asymmetry of infor-
mation in the SC causing alterations in product entry flows, pro-
ducing instability when programming and attending patients and 
their consequent costs regarding system operation.  
Model structure 
Figures 4 and 5 show the simulation model using Vensim PLE 6.0 
b software.  
Levels: 
SMED: medicine stock in a system (units) 
Flows: 
ORRE: entrance flow for drugs received in a system (units/month) 
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DISP:  outflow of drugs delivered by drugstore services 
(units/month)  
EMCP: outflow of medicines sent to preparation centres 
(units/month) 
Auxiliary variables: 
SOTR: monthly value for added consumption of drugs in 
units/month  
FCDE:  correction factor for demand  
AEPS:  approval time for treatment by a healthcare service pro-
vider (EPS) (months)  
PRTR: number of programmed treatments by HCI (units/month)  
DEST: stock deficit is the difference regarding drug stock in a sys-
tem regarding demand (units/month).  
FRAI:  risk factor regarding asymmetry of information 
ORPR: number of drug units ordered by an EPS/HCI (units/month) 
FRDM: suppliers’ market risk factor  
FRPA: risk factor rearding availability of active compound 
PROR: provider response to drug purchase order (units/month) 
LTME: provider response time (units/month) 
FRSL: logistics service risk factor 
FEDI: percenatge drugs delivered/supplied 
FECP: percentage regarding sending drugs to preparation centres 
COOR: ordering cost ($/month) 
CUOR: ordering unit cost ($/month) 
COMA: inventory maintenance cost ($/month) 
CUMA: maintenance unit cost ($/unit) 
CODI: distribution cost ($/month) 
CUDI: distribution unit cost ($/unit) 
CORI: risk cost ($/month) 
COPE: penality cost ($/unit) 
TCPE: penalty application time (month) 
 
Figure 4. Flow diagram for system operation 
 
Figure 5. Flow diagram for system costs 
Model formulation 
SMED=INTEG(ORRE-DISP-EMCP,SMEDt଴)            (1) 
ORRE= fixed delay (PROR*(1-FRSL),LTME,0)             (2) 
DISP=if then else (PRTR>=SMED,SMED*FEDI,PRTR*FEDI)     (3) 
EMCP=if then else (PRTR>SMED,SMED*FECP, PRTR*FECP)       (4) 
PRTR= fixed delay (SOTR*(1+FCDE),AEPS,0)             (5) 
DEST=if then else (PRTR>SMED, PRTR-SMED,0)       (6) 
ORPR=if then else (SMED<PRTR,(PRTR-SMED)* (1-FRAI) , 0 ) (7) 
PROR= ORPR * (1- (FRPA+FRDM))                     (8) 
COOP= CODI+COMA+COOR+CORI              (9) 
CODI= (DISP+EMCP)*CUDI                 (10) 
COMA= SMED*CUMA             (11)  
COOR= ORPR*CUOR               (12) 
CORI= fixed delay (DEST*COPE, TCPE ), 0 )           (13) 
Setting simulation and analysis runs 
Two settings were assessed by using simulation runs during a 100-
month period. The first setting included the risk factors evaluated 
in the study and their impact on system operation. The results of 
simulation in this setting (Figure 6) showed how entrance flow 
pattern was affected by risk factors, producing deficits during dif-
ferent periods due to differences between demand for and overall 
supply of drugs. 
 
Figure 6. Simulation results concerning risk scenario 
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Table 1. Average and standar deviation for data produced by simulation
Variable Mean Standard deviation 
PRTR 19,183.47 2,740.22 
AEPS 1.56 0.44 
ORPR 12,661.54 2,076.09 
PROR 7,206.38 1,370.55 
ORRE 5,139.49 1,156.13 
LTME 0.85 0.27 
DEST 14,099.30 2,255.70 
DISP 1,779.46 437.08 
EMCP 3,304.71 811.72 
The difference between stock level and treatment request in the 
system highlighted the problem of supply risk affecting SC. Out-
flow analysis led to observing system response during simulation 
time frames. 
 
Figure 7. Cost pattern in the risk scenario 
 
Figure 8. Simulation results regarding risk mitigation scenario 
 
Figure 9. Cost pattern in a risk mitigation scenario 
The cost pattern in the initial setting is presented in Figure 7 where 
the high penalty cost is reflected by the current condition of supply 
risk. 
The second setting showing the hypothetical reduction of risk fac-
tors in supply was considered by applying risk mitigation and man-
agement strategies focused on policy definition and negotiation 
rules with market provider and agent coordination, where logistics 
service operators and statement, suitability of information systems 
for management and healthcare system regulating entities were 
included. This provided cross-support for the SC and provided 
reliable information for decision-making. 
Such strategies will be defined in a subsequent stage of the study. 
However, projected values were taken on the basis of a research 
project hypothesis for assessing a mitigation setting. With this in 
mind, the simulation model was run with reduced risk factors for 
assessing the possible impact on system operation and associated 
costs. Figure 8 compares both settings. 
Figure 9 shows operating cost pattern concerning a current setting 
and a theoretical setting. 
Other more optimistic settings will enable better service and cost 
indicators. However, the hypothesis considers the complex mar-
ket dynamics surpassing regulatory control and operation 
measures in current market conditions in Colombia. 
Conclusions 
The research has presented fundamental information about the 
effects of supply risk on the oncological drug supply chain in Co-
lombia, the implications for operating costs and service level indi-
cator, presupposing an effect on the health of cancer patients.  
These results show that market response level was 56.91%, 
thereby implying a deficit in the medication system. Logistics ser-
vice supply was 71.31%, representing delays in delivery times. It 
was found that waiting time for receiving treatment was longer 
than three months in 52% of cases. On average, it is known that 
only 38 out of every 100 patients requiring drugs will actually re-
ceive them in normal conditions.  
Risk cost accounted for 70.66% of operating cases. According to 
the analysis, it was seen that the use of high cost drugs, subtituting 
doxorrubicine’s active compound, caused an increase in costs, 
therby constituting the main system cost component.  
The theoretical setting revealed that shortage ocurring due  to 
breaks in supply became reduced (obviously) where market re-
sponse level would rise from 56.91% to 85.81%, meaning that cost 
could be reduced by 21.26% in this setting. 
Future research 
The results presented in the theoretical setting showed that addi-
tional reseach on defining SC risk management strategies were 
needed for reducing risk and affecting more critical environments, 
such as system economics and cancer patients’ health. 
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